Trial to Evaluate the Safety and Efficacy of Maraviroc in Patients Hospitalized for Coronavirus Disease 2019 (COVID-19)
Status:
Completed
Trial end date:
2021-07-08
Target enrollment:
Participant gender:
Summary
Maraviroc (MVC) is a drug, very well tolerated, it has been seen that MVC has properties of
modulating the immune system, exerting an anti-inflammatory effect in different diseases. In
COVID-19, very high levels of inflammation occur that cause organs and systems to be damaged.
MVC could reduce this inflammation achieving a better prognosis of COVID-19.
Phase:
Phase 2
Details
Lead Sponsor:
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla